A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases

Abstract

Tocilizumab (TCZ) is the first humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody approved for the treatment of patients with rheumatoid arthritis (RA), Castleman’s disease, polyarticular and systemic juvenile idiopathic arthritis, and, most recently, giant cell arteritis as well as for the treatment of chimeric antigen receptor T cell therapy-induced cytokine release syndrome. The global clinical development program for TCZ provides a wealth of clinical data on intravenous TCZ, and more recent studies in patients with RA have provided evidence characterizing the role of intravenous TCZ as monotherapy in early disease and led to the introduction of a subcutaneous formulation of TCZ. In addition, recently published open-label extension and observational studies continue to support the long-term efficacy and safety of TCZ in both clinical trial and real-world settings. Given the involvement of IL-6-mediated signaling in inflammatory disorders, TCZ is also being investigated in other immunological diseases. In particular, a phase 2 trial on the safety and efficacy of subcutaneous TCZ in adults with systemic sclerosis shows clinically relevant improvements in skin sclerosis and lung function in these patients. Another anti-IL-6 receptor agent, sarilumab, targeting the IL6 receptor alpha subunit, was recently approved for the treatment of patients with RA, although long-term data for this biologic are not yet published. In this article we review the placement of TCZ in current treatment guidelines; recent clinical trial data, including quality of life in patients with RA; recent updates to the TCZ safety profile; recent investigations of TCZ in other immunological diseases; and the clinical development of other novel IL-6-targeted agents.

Tocilizumab: The First interleukin-6 Receptor-Neutralizing Biologic

Interleukin-6 (IL-6) is a multifunctional cytokine that plays an important role in both acute and chronic inflammatory responses. Consequently, the dysregulated or persistent production of IL-6 can lead to the development of inflammatory disorders [1]. Elevated levels of IL-6 in serum, synovial fluid, and various tissues have been correlated with disease activity in patients with rheumatoid arthritis (RA) [2], juvenile idiopathic arthritis (JIA) [3, 4], Castleman’s disease [5, 6], systemic sclerosis (SSc) [7], giant cell arteritis (GCA) [8, 9], adult-onset Still’s disease (AOSD) [10], familial Mediterranean fever (FMF) [11, 12], Schnitzler’s syndrome [13, 14], polychondritis [15], and amyloidosis [1]. These associations suggest a pathogenetic role for IL-6 in multiple inflammatory conditions and form the basis of the rationale for the development of anti-IL-6 therapies.

Tocilizumab (TCZ) is the first humanized monoclonal antibody targeting the IL-6 receptor subunit alpha (IL-6Rα) [16], and its mechanism of action has been described in detail in previous reviews [17, 18]. Briefly, TCZ targets both membrane-bound and soluble IL-6Rα, which prevents the binding of IL-6 to both the IL-6R and the signal transducer glycoprotein 130 complex and results in turn in inhibition of the downstream classic signaling and trans-signaling cascades involving the Janus-activated kinase-signal transducer and activator of transcription (JAK-STAT) pathway (Fig. 1) [1, 19]. Through this mechanism, TCZ decreases the circulating levels of neutrophils, neutrophil infiltration into inflamed joints [20], circulation of myeloid dendritic cells [21], monocyte levels, serum macrophage migration inhibitory factor levels [21, 22], and levels of T helper 17 (Th17) cells, while increasing regulatory T cells [23, 24]. TCZ also induces regulatory B-cell expansion, decreases B-cell hyperactivity, and decreases the number of peripheral memory B cells. Immunogenicity to TCZ (antidrug antibodies) is low [25–27].

Fig. 1.

Interleukin-6 (IL-6) signaling. IL-6 binds to and forms a complex with the IL-6 receptor and glycoprotein 130 (gp130), resulting in the homodimerization of gp130 and subsequent activation of the signaling system via classic signaling or trans-signaling pathways. The humanized anti-IL-6 receptor monoclonal antibody tocilizumab targets both soluble and membrane-bound IL-6 receptors, thus inhibiting the binding of IL-6 to both receptors. JAK Janus-activated kinase, MAPKs mitogen-activated protein kinases, SHP-2 Src-homology 2 domain-containing protein tyrosine phosphatase, STAT signal transducer and activator of transcription.

Reproduced with permission from Tanaka et al. [1]. Copyright Cold Spring Harbor Laboratory Press

In this review we briefly summarize the clinical development that supports the approval of TCZ by regulatory authorities for the treatment of Castleman’s disease, JIA, and RA that has been reviewed previously. A more detailed review is provided of the placement of TCZ in recent RA treatment guidelines; recent TCZ clinical trial data, including quality of life (QOL) in patients with RA; recent updates to the TCZ safety profile; investigations in recently approved and nonapproved immunological diseases; and the clinical development of novel IL-6-targeted agents.

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

TCZ: Brief Overview of Development for Use in Approved Indications

The key trials that contributed to the global clinical development of TCZ for use in its approved indications—RA, Castleman’s disease, systemic JIA (sJIA), polyarticular JIA (pJIA), and GCA—are shown in Fig. 2.

Fig. 2.

Global clinical development of tocilizumab (TCZ) and approval by regulatory authorities for the treatment of inflammatory disorders. DMARD Disease-modifying antirheumatic drug, EU European Union, GCA giant cell arteritis, IR inadequate responder, LTE long-term extension, MTX methotrexate, OL open-label, pJIA polyarticular juvenile idiopathic arthritis, RA rheumatoid arthritis, SC subcutaneous, sJIA systemic juvenile idiopathic arthritis,TNFi tumor necrosis factor inhibitor, US United States of America

Castleman’s Disease

In 2005, TCZ was initially approved for the treatment of Castleman’s disease in Japan, where it significantly alleviated chronic inflammatory symptoms and wasting and demonstrated good tolerability [16].

Juvenile Idiopathic Arthritis

The results of Japanese phase 3 trials demonstrated that TCZ effectively treated children with systemic and pediatric JIA (sJIA and PJIA, respectively), as measured by JIA American College of Rheumatology (ACR) response rates. This resulted in its approval for both indications in Japan in 2008 [28, 29]. In 2011, TCZ was approved in the USA and the European Union (EU) for the treatment of sJIA, and in 2013, for the treatment of pcJIA based largely on phase 3 data from the TENDER and CHERISH trials, in which the signs and symptoms of sJIA and pcJIA, respectively, were improved in children treated with TCZ compared to placebo [30, 31].

Giant Cell Arteritis

Tocilizumab was approved for the treatment of patients with GCA, a vasculitis of medium- and large-sized arteries, by the U.S. Food and Drug Administration (FDA) on 22 May 2017 and by the European Commission on 22 September 2017, making this the first drug approved for the treatment GCA beyond glucocorticoids, which are associated with substantial morbidity from glucocorticoid-related complications following prolonged use [32].

Analysis of biopsy specimens from patients with GCA using quantitative real-time PCR identified proinflammatory pathogenic pathways mediated by Th17, which promotes the release of IL-1β, IL-6, and IL-23 cytokines, and of Th1, which promotes the release of IL-12 cytokines; these cells contribute to the systemic and vascular manifestations of GCA [33]. As a result, biologic therapies targeting these proinflammatory pathways are logical targets for the treatment of GCA.

The published results of a randomized double-blind phase 2 trial of TCZ in patients with GCA were the first to demonstrate the induction and maintenance of remission in a clinical trial setting [34]. Compared to the placebo group, the TCZ group had higher rates of complete remission at week 12 (85 vs. 40%) and higher relapse-free survival at week 52 (85 vs. 20%).

Recently, a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial (GiACTA) of TCZ in patients with GCA showed that TCZ + a 26-week prednisone taper was superior to both 26-week and 52-week prednisone tapers alone for the achievement of sustained remission from GCA [35]. Sustained remission at 12 months was achieved by 56% of patients receiving weekly TCZ + 26-week prednisone taper and 53.1% of those receiving every-other-week TCZ + 26-week prednisone taper, compared with 14% of patients receiving the 26-week prednisone taper alone (P < 0.0001 for both comparisons). Both TCZ groups were also superior to the 52-week prednisone taper alone group in terms of sustained remission from GCA (P ≤ 0.0002). The addition of TCZ to prednisone treatment in the GiACTA trial also allowed a reduction in the cumulative prednisone doses required for disease control, with a median cumulative steroid exposure of 1862.0 mg in both TCZ groups compared with 3817.5 mg in the 52-week prednisone taper group and 3296.0 mg in the 26-week prednisone taper group [35]. Kaplan–Meier analysis of data from GiACTA demonstrated that patients with higher TCZ exposure (i.e., those receiving weekly TCZ) experienced a longer time to first flare of GCA [36].

In summary, TCZ is now approved for the treatment of GCA, and the findings of the GiACTA trial indicate that early initiation of TCZ therapy in patients with GCA allows the reduction of glucocorticoid use and cumulative glucocorticoid dose and achieves a reduced flare rate.

Chimeric Antigen Receptor T-Cell Therapy-Induced Cytokine Release Syndrome

In August 2017, TCZ was approved by the FDA for the treatment of chimeric antigen receptor (CAR) T-cell therapy-induced cytokine release syndrome [37]. This approval was based on retrospective analysis of pooled data from clinical trials of CAR T-cell therapies for blood cancers [38].

Rheumatoid Arthritis

Early Clinical Development in RA

The initial clinical development of TCZ for the treatment of RA has been reviewed previously [39]. Five randomized, double-blind, controlled, multicenter, phase 3, pivotal clinical trials were central to the approval of TCZ by regulatory authorities of TCZ in the EU and the USA for the treatment of RA (Fig. 2) [40–44]. Briefly, OPTION [42] and TOWARD [43] together showed that treatment with TCZ at 4 and 8 mg/kg body weight in combination with methotrexate (MTX) or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) reduced the signs and symptoms of RA in patients who responded inadequately to MTX/csDMARDs alone. The LITHE trial [41] demonstrated a greater inhibition of structural joint damage and greater improvement in physical function with TCZ 4 and 8 mg/kg + MTX than with MTX alone in patients with RA who were inadequate responders to MTX alone. The RADIATE trial [44] showed that TCZ prescribed at 4 and 8 mg/kg reduced the signs and symptoms of RA in patients who responded inadequately to treatment with tumor necrosis factor (TNF) inhibitors. The AMBITION trial [40] showed that montherapy with TCZ at 8 mg/kg was superior to monotherapy with MTX in terms of improving signs and symptoms of RA in patients for whom previous treatment with MTX or biologics had not failed.

Dosing and Dose–Response in RA

The recommended initial dosing regimen for TCZ in patients with RA differs between the EU and the USA. A starting dosage of TCZ 8 mg/kg every 4 weeks is recommended in the EU [45], whereas a starting dosage of 4 mg/kg every 4 weeks is recommended in the USA, with the option of increasing to 8 mg/kg based on clinical response and at the treating physician’s discretion [37].

The five pivotal phase 3 studies of TCZ suggested a possible dose response for TCZ 4 and 8 mg/kg; however, the studies were not powered to detect differences between the two dosing regimens [40–44]. Numerical differences in efficacy outcomes were evident between dosing at TCZ 4 and 8-mg/kg, suggesting that some patients may respond well to TCZ 4 mg/kg.

Real-world data show that a large proportion of patients in the USA increase their TCZ dosage from 4 to 8 mg/kg soon after initiating treatment. Analysis of data from patients with RA in the comparative-effectiveness CERTAIN substudy nested within the U.S. Corrona Registry revealed patterns of TCZ dose escalation in a real-world setting [46]. Among the patients with RA who initiated TCZ treatment and completed the visits at the predetermined 3- and 6-month time points in this substudy (N = 213), 86 (40.4%) remained on the initial dosage of 4 mg/kg and 110 (51.6%) increased their dosage to 8 mg/kg by 3 months [46]. Improvements in measures of disease activity and moderate or good European League Against Rheumatism (EULAR) response rates were also observed at 3 and 6 months in both groups, suggesting that flexibility in dosing may be possible [46]. Although the sample size of the Corrona analysis was small, the results are consistent with those from an analysis of U.S. healthcare claims data that included 3600 patients with RA who received TCZ intravenously between January 2016 and April 2017. During this period, 31% of patients received TCZ 4 mg/kg, 42% received TCZ 8 mg/kg, and 27% switched between the two dosing regimens over the course of the observation period (83% switched from 4 to 8 mg/kg). Furthermore, data between May 2016 and April 2017 indicated stable dosing patterns over 12 months, with approximately 64% of patients receiving TCZ 8 mg/kg (Symphony Health Source Healthcare Analytics claims, unpublished data). Subcutaneous (SC) administration of TCZ was received weekly in 66% of patients and biweekly in 34% of patients between January 2016 and April 2017 (Symphony Health Source Healthcare Analytics claims, unpublished data). Although the sample size and methodology for this U.S. claims data analysis differed from that of the Corrona analysis, both analyses indicated that a substantial proportion of patients switched from TCZ 4 mg/kg to TCZ 8 mg/kg.

In summary, there is some indication of a dose–response relationship with TCZ, but this does not apply to all patient populations. It is the authors’ impression that based on numerical trends, there will be some patients who respond well to the 4 mg/kg dosing regimen. Although data are sparse, some patients may be able to decrease their dosage from 8 to 4 mg/kg after a period of disease control.

Update on QOL and Patient-Reported Outcomes in RA

A systematic literature review of randomized controlled trials of TCZ in patients with RA reported improved physical function and QOL [47]. TCZ was associated with greater improvements in disease-related function (as measured by the Health Assessment Questionnaire Disability Index [HAQ-DI]) and QOL (measured with the 36-Item Short Form Health Survey [SF-36]) compared with control treatments (placebo, MTX, or csDMARDs); the odds ratio for improvement in HAQ-DI was 1.4 for controls versus 7.0 in favor of TCZ [47]. Improvements exceeding minimal clinically important differences (MCIDs) were reported for the SF-36 Physical Component Summary (PCS; MCID 5.0), SF-36 Mental Component Summary (MCS; MCID 5.0), and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale scores (MCID 4.0) [47].

Taken together, data from eight phase 3 or 4 trials also support clinically relevant improvements in HAQ-DI scores (MCID > 0.5). Results from the TCZ treatment groups in these trials were generally statistically significantly better than those in the comparator groups, although improvements in HAQ-DI scores were often observed in the comparator groups as well [48–55]. For example, the ADACTA trial comparing TCZ monotherapy to adalimumab monotherapy demonstrated mean HAQ-DI score improvements of − 0.7 for TCZ and − 0.5 for adalimumab (difference in adjusted means: − 0.2; 95% confidence interval [CI] − 0.3 to 0.0; P = 0.0653). A higher proportion of TCZ-treated patients than adalimumab-treated patients reported improvement in HAQ-DI scores of at least a MCID of 0.22 (92/163 [56.4%] vs. 83/162 [51.2%], respectively), although there was no statistically significant difference [49]. Altogether, improvements in QOL were observed in patients who were MTX naive [51, 52], MTX inadequate responders (or with contraindication or intolerance to MTX) [48, 49, 53], csDMARD inadequate responders [50, 54], and TNF inhibitor inadequate responders [55]. The duration of response reported varied from 24 to 104 weeks, which is in line with the duration of each trial [48–51, 53–55], except for one trial in which improvement in HAQ-DI scores was observed at week 24, but not at weeks 52 or 104 [52].

Changes in the SF-36 PCS and MCS scores have been reported in two phase 3 trials and in a post hoc analysis of the RADIATE trial [49, 51, 55]. The ADACTA trial reported improvements in SF-36 PCS scores of 9.2 for TCZ 8 mg/kg and 7.6 for adalimumab (both greater than the MCID but not statistically significantly different between treatment groups; P = 0.1641); SF-36 MCS scores were 7.9 and 5.0, respectively (P = 0.0497) [49]. Similar results were reported for both the FUNCTION and RADIATE trials [51, 55].

Improvements in fatigue, as assessed by the FACIT Fatigue Scale, were observed for both TCZ and adalimumab in the ADACTA trial (adjusted mean change to week 24 was 11.4 for TCZ and 8.9 for adalimumab; difference: 2.5; 95% CI − 0.3 to 5.3; P = 0.0770) [49] and for TCZ in a post hoc analysis of the RADIATE trial (mean changes to week 24 were 6.66 for TCZ 4 mg/kg and 8.83 for TCZ 8 mg/kg) [55].

In summary, the results of randomized controlled clinical trials show that TCZ improves health-related activities of daily living and other aspects of QOL, such as the domains of the SF-36 and the FACIT Fatigue Scale. Although patient-reported outcome studies are often uncontrolled and subject to problems of selection and outcome bias, they provide important supportive data suggesting that TCZ is associated with improving these outcomes.

TCZ: Recent Developments in RA

The recent development of TCZ use in the RA setting includes evidence further characterizing its use as monotherapy and in patients with early RA, as well as the introduction of an SC formulation of TCZ (TCZ-SC). Furthermore, recently published open-label extension (OLE) and observational studies inform the long-term efficacy and safety of TCZ beyond 2 years.

TCZ as Monotherapy

Two randomized, double-blind, controlled clinical trials assessed TCZ as monotherapy in patients with active RA despite an inadequate response to MTX (ACT-RAY) [56] and, separately, in patients with severe RA who were intolerant to or inappropriate for continued MTX treatment (ADACTA) [49].

The phase 3 ACT-RAY trial demonstrated that there were no clinically relevant differences between adding TCZ 8 mg/kg to the MTX therapeutic regimen (mean disease duration at baseline 8.2 years) and switching to monotherapy with TCZ 8 mg/kg (mean disease duration at baseline: 8.3 years) after 24 weeks of therapy when disease activity was measured using the Disease Activity Score based on 28 joints (DAS28) and erythrocyte sedimentation rate (ESR) remission (DAS28-ESR < 2.6; 40.4% in the add-on group vs. 34.8% in the monotherapy group). There were also no relevant differences in the assessments of radiographic progression of structural damage (Genant-modified Sharp score progression of the smallest detectable change or less: 91 vs. 87%) [56]. These efficacy measures were maintained at week 52 for both DAS28-ESR-defined remission (45.5 vs. 36.6% and p = 0.03) and radiographic progression (92.8 vs. 86.1% of patients) [57].

In the phase 4 ADACTA trial, monotherapy with TCZ 8 mg/kg (mean disease duration at baseline 7.3 years) was superior to monotherapy with the TNF inhibitor adalimumab 40 mg every 2 weeks (mean disease duration at baseline 6.3 years) in incomplete responders to MTX (inadequate response, contraindication, or intolerance to MTX). Reductions from baseline in the DAS28-ESR were significantly greater with TCZ than adalimumab (− 3.3 vs. − 1.8; P < 0.0001).

The FUNCTION trial in MTX-naive patients with early RA (mean disease duration at baseline 0.4–0.5 years) [51] and the SURPRISE trial in patients with inadequate response to MTX (mean disease duration at baseline 3.6–3.8 years) [58] included TCZ + MTX combination therapy and TCZ monotherapy treatment arms. Although the FUNCTION trial was not powered for comparisons between TCZ combination therapy and TCZ monotherapy, the TCZ 8 mg/kg + MTX group consistently achieved the best outcomes for all efficacy measures, including DAS28-defined remission [51]. The SURPRISE trial reported higher rates of DAS28-defined remission in patients who added TCZ to their MTX treatment regimen compared with those who switched from MTX to TCZ at week 24 (primary end point), but the DAS28-defined remission rates were not significantly different at week 52 or for other efficacy end points, and there was no significant difference in rates of structural remission or clinically relevant radiographic progression (change in the modified total Sharp score [mTSS] ≥ 3) between the add-on and the switch groups. However, among seven add-on and 15 switch patients who did experience clinically relevant radiographic progression, the mean change in total mTSS was greater in the switch group than in the add-on group (9.0 vs. 5.0/year; P = 0.04), suggesting that adding TCZ to MTX monotherapy may lead to superior clinical efficacy and prevent joint destruction compared with switching from MTX to TCZ monotherapy [58].

In summary, in patients with disease duration ranging between 6.7 and 8.3 years, monotherapy with the intravenous formulation of TCZ (TCZ-IV) at 8 mg/kg seems to be as effective as adding TCZ to MTX monotherapy (combined TCZ + MTX therapy) for incomplete responders to MTX monotherapy. TCZ added to MTX may provide some benefit over TCZ monotherapy in patients with shorter disease duration, but this therapeutic option needs further investigation.

SC Formulation of TCZ

Two randomized, double-blind, comparative, phase 3 studies demonstrated the noninferiority of TCZ-SC to TCZ-IV according to standard outcome measures/response rates of the ACR for 20% improvement (ACR20) at week 24 in patients with RA and an inadequate response to csDMARDS and/or biologic DMARDS (bDMARDs; MUSASHI trial) [59] or to only csDMARDs (SUMMACTA trial) [50]. In addition, similar rates of ACR50 (50% improvement) and ACR70 (70% improvement) responses between TCZ-SC and TCZ-IV were reported [50, 59].

An 84-week OLE of the MUSASHI trial demonstrated maintenance of efficacy for DAS28-ESR-defined remission rates between patients continuing TCZ-SC treatment and those switching from TCZ-IV to TCZ-SC [60]. The long-term efficacy and safety of TCZ-SC was also maintained through 97 weeks and found to be comparable to that of TCZ-IV in a 72-week OLE of the SUMMACTA study [54]. TCZ-SC is approved in Japan, the USA (2013), and the EU (2014) for adult patients with RA [37, 45].

The single-arm, open-label, multinational, phase 4 TOZURA trial is currently evaluating the efficacy and safety of 24 weeks of treatment with weekly TCZ-SC 162 mg as either monotherapy or in combination with a csDMARD (at the investigator’s discretion) in patients with RA who had an inadequate response to bDMARDs or csDMARDs [61]. An interim analysis of 1246 patients demonstrated equivalent DAS28-ESR and Clinical Disease Activity Index remission rates for both TCZ monotherapy and combination therapy at week 24. These interim results are promising and completed results are anticipated.

In summary, TCZ-SC appears to be as effective as TCZ-IV with comparable safety (discussed below in section Safety, Pharmacokinetics, and Immunogenicity).

TCZ in Early RA

Two randomized, double-blind, multicenter, phase 3 trials have studied TCZ in MTX-naive patients with early (≤ 2 years) progressive RA (FUNCTION trial) [51] and in DMARD-naive patients (U-ACT-Early study) [52]. The 2-year U-ACT-Early study demonstrated that more patients treated with TCZ 8 mg/kg monotherapy and TCZ 8 mg/kg + MTX combination therapy achieved sustained remission and low disease activity (DAS28-ESR < 2.6 with swollen joint count ≤ 4, persisting for ≥ 24 weeks) than those treated with MTX alone (84 and 86% vs. 44%, respectively; both P < 0.0001), with no significant differences between TCZ monotherapy versus combined TCZ + MTX therapy [52]. In the FUNCTION trial, patients treated with TCZ 8 mg/kg monotherapy and TCZ 8 mg/kg + MTX achieved significantly higher rates of DAS28-ESR-defined remission at week 24 than those treated with MTX monotherapy (44.8 and 38.7% vs. 15%, respectively; P < 0.0001), with similar clinical efficacy observed between TCZ monotherapy and the combination therapy [51]. The difference in remission rates between these two studies may possibly be ascribed to approximately 20% of the FUNCTION study population having previously received one or more csDMARD [51], whereas patients enrolled in the U-ACT-Early trial were csDMARD-naive [52].

In summary, in patients with < 2 years of disease duration, these two studies demonstrate that TCZ 8 mg/kg monotherapy or combined TCZ 8 mg/kg + MTX therapy improved DAS28-ESR-defined remission rates compared to MTX monotherapy and that adding MTX to TCZ therapy did not improve TCZ response. In 2014, TCZ received approval in the EU for use in early RA (i.e., severe, active, and progressive RA not previously treated with MTX) [45].

Long-Term OLE and Observational Studies

Although several OLE and observational studies of < 2 years’ duration have been conducted, this section focuses on those with a study duration > 2 years to provide more clinically relevant findings.

Inhibition of radiographic progression was maintained through 5 years in a 3-year OLE study of the LITHE trial, with less radiographic progression observed for patients originally randomly assigned to receive TCZ than for those originally assigned to receive placebo (Genant-modified TSS 1.34 and 3.02, respectively) [62].

The long-term clinical efficacy of TCZ monotherapy in patients with RA who were MTX- or biologic-naive was also assessed in an OLE of the AMBITION trial, which reported sustained improvements in DAS28-ESR-defined remission and ACR response rates through 264 weeks of follow-up in patients remaining on their study medication [63]. A multicenter prospective observational cohort study evaluating clinical responses and radiographic end points for TCZ during 3 years of treatment in Japanese patients with RA reported sustained (≥ 6 months) reductions in DAS28-ESR scores, along with improvements in both clinical (Boolean remission) and structural (Genant-modified TSS) remission rates during 3 years of follow-up [64].

In summary, these studies support the long-term efficacy of TCZ-IV in patients remaining on TCZ treatment, in both clinical trial follow-up studies and real-world observational cohorts. A long-term decrease in the rate of radiographic progression is also demonstrated.

Safety, Pharmacokinetics, and Immunogenicity

The safety of TCZ-IV and TCZ-SC has been reported in 11 published phase 3 and 4 trials [40, 42–44, 49–52, 56, 59, 65]. The most common adverse events (AEs) and serious AEs (SAEs) reported in patients with RA treated with TCZ in these trials were infections, such as nasopharyngitis, upper respiratory tract infections, pneumonia, and cellulitis. Other SAEs of interest reported in patients with RA treated with TCZ include gastrointestinal perforations (GIPs), malignancy, myocardial infarction, and stroke. Abnormalities in laboratory test results have also been reported, including elevated liver enzyme levels, decreased neutrophil counts, and changes in lipid levels. Other safety signals were not identified in a cumulative analysis of up to 4.6 years of TCZ exposure based on pooled data from the OPTION, TOWARD, RADIATE, AMBITION, and LITHE phase 3 trials (with 12,293 patient-years of exposure) compared with the placebo-controlled periods; infections were the most common AEs and SAEs [66]. As of 7 June 2017, the estimated cumulative TCZ exposure in the periodic benefit–risk evaluation report is > 700,000 patient-years (F. Hoffmann–La Roche Ltd., data on file).

A higher incidence of GIPs and specifically lower intestinal perforations (LIPs) has been reported in patients treated with TCZ than in those treated with other biologics or csDMARDs (rates per 1000 patient-years: GIPs, 1.8–2.8 for TCZ vs. 0.6–0.9 for TNF inhibitors [difference: 1.2 − 1.9/1000 patient-years]; LIPs, 1.26–2.7 for TCZ vs. 0.2–0.76 for TNF inhibitors) [67–69]. For every 1000 patients treated with TCZ per year, between one and two additional GIPs might be expected to occur for patients treated with TCZ compared with those treated with TNF inhibitors [69]. In particular, the risk for LIPs seems to be higher in patients with a history of diverticulitis [67, 68], indicating that TCZ should be avoided in patients at risk for GIP. Furthermore, TCZ-treated patients with LIP often exhibit only mild or no symptoms and suppressed C-reactive protein (CRP) levels, which may delay diagnosis [67]. These findings indicate a class effect for anti-IL-6 agents, highlighting the need for careful patient selection (i.e., exclusion of individuals with previous diverticulitis) in clinical trials evaluating TCZ and other anti-IL-6 agents in order to reduce the risk for LIP.

Neutropenia and malignancy are two additional safety issues of interest for patients receiving TCZ. In a retrospective cohort study of patients with rheumatic diseases, TCZ was associated with a higher incidence of neutropenia compared with abatacept and infliximab (18.6% vs. 3.8% and 2.8%, respectively; P < 0.001). This increased incidence of neutropenia did not result in a higher risk for severe infections [70]. Despite concerns for the risk for malignancy during immunosuppressive therapy in patients with RA, an analysis of phase 3 trials and long-term extension studies did not demonstrate increased risk for overall or site-specific malignancies above the risk expected in patients with RA [71]. However, patients treated with TCZ should be monitored for malignancies to provide data that can be used for to assess risk over the longer term.

The data for the pharmacokinetics (PK) of TCZ-IV and TCZ-SC are based on population PK analyses of 1793 and 1759 patients with RA, respectively [72–74]. In addition, population PK analyses of 75 patients with sJIA and 188 patients with pJIA have been conducted to determine the PK of TCZ-IV in these patients (F. Hoffmann–La Roche Ltd., data on file). We have summarized the PK profiles in Table 1 [37, 72, 73]. PK exposure parameters for TCZ were found to be similar between healthy individuals and patients with RA, indicating that even the presence of active disease does not impact the PK profile of TCZ [74]. The PK profile of TCZ is not affected by alcohol, age, or ethnicity. In addition, no clinically relevant additive effects on the PK profiles of TCZ and MTX were observed when they were administered together in patients with RA [72, 75]. This result was also supported by the FUNCTION trial, which reported similar serum TCZ levels in patients receiving or not receiving MTX in combination with TCZ [51].

Table 1.

Summary of the pharmacokinetics profiles for the intravenous and subcutaneous formulations of tocilizumab in patients with rheumatoid arthritis, systemic juvenile idiopathic arthritis (JIA), and polyarticular JIA [37, 72, 73]

PK parameter	Rheumatoid arthritis				sJIA	pJIA
	TCZ-IV		TCZ-SC		TCZ-IV	TCZ-IV
	4 mg/kg every 4 weeks	8 mg/kg every 4 weeks	162 mg every weeks	162 mg every other weeks	8 mg/kg (BW ≥ 30 kg) or 12 mg/kg (BW < 30 kg) every 2 weeks	8 mg/kg (BW ≥ 30 kg) every 4 weeks	10 mg/kg (BW < 30 kg) every 4 weeks
Estimated mean steady state AUC (SD), µg/h/mL	13,000 (5800)	35,000 (15,500)	8200 (3600)	3200 (2700)	32,200 (9960)	29,500 (8660)	23,200 (6100)
Estimated mean steady state Cmin (SD), µg/mL	1.49 (2.13)	9.74 (10.5)	44.6 (20.6)	5.6 (7.0)	57.5 (23.3)	7.49 (8.2)	2.35 (3.59)
Estimated mean steady state Cmax (SD), µg/mL	88.3 (41.4)	183 (85.6)	50.9 (21.8)	12.3 (8.7)	245 (57.2)	182 (37)	175 (32)
t1/2 (days)	~ 11	~ 13	~ 13	~ 5	NA	NA	NA
Volume of distribution (L)
Central	3.5		4.5		NA	NA	NA
Peripheral	2.9		2.8		NA	NA	NA
Bioavailability (%)	NA	NA	79.5		NA	NA	NA
Clearance (L/day)	0.3		0.216		NA	NA	NA

AUC Area under the concentration curve, BW body weight, C_max maximum concentration, C_min minimum concentration, IV intravenous, NA not available, pJIA polyarticular juvenile idiopathic arthritis, PK pharmacokinetics, SC subcutaneous, SD standard deviation, sJIA systemic juvenile idiopathic arthritis, t_1/2 half-life, TCZ tocilizumab

Clinical experience with both TCZ-IV and TCZ-SC has demonstrated low immunogenicity in several indications, including RA [76], Castleman’s disease [16], and JIA [28, 29, 31]. In a pooled analysis of data from 13 phase 3 clinical trials (8 TCZ-IV, 5 TCZ-SC) and one TCZ-IV safety study, antidrug antibodies were identified in 47 of 3094 (1.5%) and 69 of 5806 (1.2%) patients treated with TCZ-SC and TCZ-IV, respectively [76]; neutralizing antidrug antibodies were confirmed in 40 of 3094 (1.3%) and 54 of 5806 (0.9%) of these patients, respectively [76].

In summary, the safety, PK, and immunogenicity of TCZ-SC appear to be similar to those for TCZ-IV.

The Role of TCZ in Current Treatment Regimens for RA

Tocilizumab has been incorporated as a treatment option into current ACR and EULAR recommendations for the management of RA [77, 78]. ACR 2015 guidelines recommend that a non-TNF biologic (rituximab or TCZ), with or without MTX, can be considered if disease activity remains moderate or high despite the use of csDMARDs or after failure of TNF inhibitor treatment [77]. EULAR 2016 updated guidelines recommend TCZ as a bDMARD option [78]. A treatment target of sustained remission or low disease activity is recommended in the guidelines for every patient, with the goal of achieving sustained remission. For patients who do not improve or reach their target end point after receiving csDMARDs for 3–6 months, a bDMARD or a targeted synthetic DMARD (tsDMARD), such as tofacitinib or baricitinib, should be added to the treatment regimen. The guidelines state that bDMARDs should usually be initiated in combination with a csDMARD except in patients who cannot use them as comedication, in which case IL-6 pathway inhibitors and tsDMARDs may offer some advantages over other bDMARDs.

In summary, updated guidelines regarding csDMARDs, bDMARDs, and tsDMARDs include the use of non-TNF-inhibitor biologics, such as TCZ (abatacept or rituximab) and place these drugs in the RA armamentarium. However, the specific position of TCZ in the treatment algorithm is yet to be determined.

TCZ: Promising Research, Including Potential Indications

Systemic Sclerosis

Given that IL-6 is involved in both innate and adaptive immune responses, inhibition of IL-6-mediated signaling with TCZ may be an effective therapeutic approach for the treatment of SSc. Initial clinical experience with TCZ in SSc includes softening of the skin and histological thinning of the collagen fiber bundles in the dermis of two patients with SSc [79], while a small observational study of patients with SSc and refractory polyarthritis reported the achievement of a good EULAR response in 10 of 15 patients [80]. In the recent double-blind phase 2 faSScinate trial, there was encouraging (although not statistically significant) numerical improvement in skin thickening and evidence of less decline in lung function in adult patients with progressive SSc treated with TCZ-SC compared to those receiving placebo [81]. Further studies are needed, and an ongoing 2-year randomized phase 3 trial of TCZ-SC 162 mg in SSc is under way (ClinicalTrials.gov identifier NCT02453256).

Steroid Sparing in RA

A trial assessing the steroid-sparing ability of TCZ (SEMIRA trial; ClinicalTrials.gov identifier NCT02573012) is currently in progress. The aim of this study is to evaluate the efficacy of maintenance treatment with TCZ-SC or TCZ-IV with or without stable doses of csDMARD in patients with RA who have DAS-defined low disease activity (≤ 3.2) for ≥ 4 weeks before randomization and have been receiving glucocorticoids (5–15 mg/day of prednisone or equivalent) for ≥ 20 weeks before screening. Eligible patients were randomly assigned to receive either a blinded 24-week prednisone tapering regimen or a blinded continuation of prednisone 5 mg/day for 24 weeks. Patient recruitment for the SEMIRA trial is now completed and the results are pending.

Other Diseases

Given the far-reaching involvement of IL-6-mediated signaling in inflammatory disorders, TCZ is being investigated in a number of other diseases.

The TENOR trial was a prospective, open-label, longitudinal, multicenter study evaluating TCZ therapy in patients with polymyalgia rheumatica (PMR); significant reductions in ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake (assessed by positron emission tomography-computed tomography) following TCZ therapy suggested a decrease in disease activity [82]. Additionally, the randomized, double-blind, placebo-controlled, phase 3 SEMAPHORE trial is recruiting patients and will evaluate the safety and efficacy of TCZ in patients with PMR who are glucocorticoid dependent (ClinicalTrials.gov identifier NCT02908217).

A small multicenter study of 11 patients with uveitis associated with Behçet’s disease reported improvements in visual acuity, number of blood cells in the anterior chamber of the eye, vitritis, retinal vasculitis, optical coherence tomography, achievement of complete remission, and prednisone dose reduction in patients receiving TCZ therapy [83]. Early-phase trials are under way to evaluate both TCZ-IV (ClinicalTrials.gov identifier NCT01717170) and TCZ-SC (ClinicalTrials.gov identifier NCT02929251) in patients with noninfectious uveitis.

No published prospective clinical trials evaluating TCZ in AOSD are available, but promising efficacy results have been observed in several case reports and retrospective analyses [84–87]. Improvements in clinical (fever, rash, and myalgia) and laboratory (ESR and CRP) manifestations were observed after treatment with TCZ in a review of 24 cases of AOSD in Korean patients [88]. A multicenter study of 75 patients with AOSD treated with TCZ or anakinra also reported similar improvements in clinical manifestations (fever, articular, rash, and lymphadenopathy) over 12 months of therapy between the two study treatments, although improvements in CRP and ESR levels appeared to be greater with TCZ than with anakinra [89]. Furthermore, the preliminary results of a small, prospective, single-arm pilot study in eight patients recently reported no significant AEs with TCZ monotherapy and improvement rates of 100% for fever, 75.0% for arthralgia, and 71.4% for eruption at 6 months in patients with AOSD [90].

Evidence from case reports, small studies, and retrospective studies suggest that TCZ may be an effective therapeutic option in vasculitis syndromes other than GCA, including systemic rheumatoid vasculitis, PMR, Takayasu arteritis, and Behçet’s disease [91–96]. TCZ has also shown promise in several other indications, including amyloidosis [97–100], FMF [101–103], Schnitzler’s syndrome [104, 105], and polychondritis [106–109]. Results of the double-blind, randomized, placebo-controlled, phase 3 TAKT trial in 36 patients with Takayasu arteritis demonstrated a trend toward relapse suppression in favor of TCZ-SC over placebo [110]. However, the primary end point (time to first protocol-defined relapse) was not met in the intent-to-treat population (hazard ratio = 0.41; 95.41% CI 0.15–1.10; P = 0.0596). TCZ-SC showed numerically favorable (though not statistically significant) trends for improvement in objective systemic symptoms, subjective systemic symptoms, elevated inflammation marker levels, vascular lesions, and ischemic symptoms accompanied by organ lesions in the TAKT trial [110]. TCZ was approved in August 2017 for the treatment of Takayasu arteritis in Japan based on the results of the TAKT study.

Clinical studies evaluating TCZ in patients with ankylosing spondylitis have been conducted, but they failed to demonstrate efficacy [111, 112]. Ongoing trials are under way to assess TCZ in a range of disorders, such as hand osteoarthritis, new-onset type 1 diabetes, diabetic macular edema, myocardial infarction, pulmonary arterial hypertension, psychiatric disorders (e.g., schizophrenia, schizoaffective disorder, and major depressive disorder), primary Sjögren’s syndrome, hepatocellular carcinoma, chronic lymphocytic leukemia, refractory dermatomyositis and polymyositis, amyotrophic lateral sclerosis, graft-versus-host disease, and human immunodeficiency virus (HIV) infection.

In summary, case reports and observational or retrospective studies indicate that further studies of TCZ may be appropriate for AOSD, Behçet’s disease, other vasculitides, FMF, and polychondritis. IL-6 is a pleotropic cytokine with multiple effects and its inhibition is leading to a large variety of clinical trials in multiple diseases. Results from these trials will likely guide further studies into other indications.

Other IL-6-Targeted Biologics

Novel biologics that target IL-6 signaling are undergoing clinical development in the RA setting, including human anti-IL-6R alpha (sarilumab, approved in the USA on 22 May 2017 for the treatment of RA) and anti-IL-6 cytokine (olokizumab, sirukumab, and clazakizumab) monoclonal antibodies. Interestingly, blockade of the IL-6R (e.g., with TCZ or sarilumab) may be associated with distinct clinical effects from blockade of the IL-6 cytokine (e.g., with sirukumab or clazakizumab). Use of a human primary cell-based phenotypic screening system (BioMAP®; DiscoverX, Fremont, CA, USA; now part of Eurofins Scientific, Brussels, Belgium) demonstrated that sirukumab and TCZ had BioMAP phenotypic signatures that were distinct from each other, suggesting that the impact of TCZ on IL-6R signaling is distinct from that of sirukumab [113]. Nevertheless, preliminary evidence to date indicates that these novel IL-6-targeted biologics show promise with regard to their long-term efficacy and safety.

Sarilumab

Sarilumab has been approved in the USA and EU for the treatment of patients with RA who have an inadequate response to MTX or csDMARDs. This approval was based on the positive findings of two pivotal phase 3 clinical trials, MOBILITY and TARGET, in which a total of 1164 patients were exposed to sarilumab.

Sarilumab was investigated in MOBILITY, a phase 3 trial of patients with RA who had inadequate response to MTX [114]. Therapy with sarilumab 150 or 200 mg every 2 weeks in combination with MTX was associated with significant improvements compared with placebo + MTX, according to ACR20 response rates at week 52 (58.0 and 66.4% vs. 33.4%), changes from baseline to week 16 in HAQ-DI physical function scores (− 0.53 and − 0.55 vs. − 0.29), and the change from baseline to week 52 in the Sharp/van der Heijde radiographic scores (0.90 and 0.25 vs. 2.78) (all P < 0.0001). An OLE study (EXTEND; ClinicalTrials.gov identifier NCT01146652) of the MOBILITY trial also demonstrated that sarilumab 200 mg provided durable clinical response and stabilization of radiographic progression at 3 years [115]. Furthermore, most patients who reduced their dosage of sarilumab from 200 to 150 mg every 2 weeks in the OLE study demonstrated sustained efficacy with regard to ACR20 response rate (83.1%) and improvements in HAQ-DI scores (− 0.68), along with continued improvements in abnormalities in laboratory test results, signs and symptoms of RA, and physical function [116].

The randomized, double-blind, head-to-head, phase 3 MONARCH trial demonstrated that sarilumab 200 mg was superior to adalimumab with regard to the change from baseline in DAS28-ESR (− 3.28 vs. − 2.20; P < 0.0001) in patients with RA and inadequate response to MTX [117].

Results of the randomized phase 3 TARGET trial (ClinicalTrials.gov identifier NCT01709578), which evaluated sarilumab + csDMARD therapy in patients with RA who were inadequate responders to or intolerant of TNF inhibitors, demonstrated that sarilumab 150 mg and 200 mg every 2 weeks were associated with significant improvements in ACR20 response rates at week 24 (56 and 61% vs. 34%; both P < 0.0001) and HAQ-DI physical function scores at week 12 (− 0.50 and − 0.49 vs. − 0.29; both P < 0.001), compared to placebo [118]. Analyses of the TARGET trial data also showed significant and clinically meaningful improvements from baseline in patient-reported outcomes (fatigue, morning stiffness, pain, and work productivity) and significant reductions in levels of biomarkers of bone resorption and joint damage with sarilumab [119, 120]. Complete published results of these analyses are pending. Published results are also pending for the randomized phase 3 ASCERTAIN trial (ClinicalTrials.gov identifier NCT01768572), which evaluated SC sarilumab 150 mg or 200 mg every 2 weeks and TCZ-IV 4 mg/kg increased to 8 mg/kg based on clinical response in patients receiving background csDMARDs who had an inadequate response to or were intolerant of TNF inhibitors. Preliminary results do not show clinically meaningful differences between sarilumab 150 mg or 200 mg and TCZ with regard to treatment-emergent AEs (67, 71, and 67%, respectively), SAEs (2, 6, and 7%, respectively), or serious infections (0, 2, and 2%, respectively) [121].

Olokizumab

Olokizumab was evaluated in a phase 2b trial in 221 patients with RA who had an inadequate response to TNF inhibitor therapy. DAS28-CRP-defined improvements from baseline to week 12 for olokizumab versus placebo (− 1.16 to − 2.68 vs. − 0.19 to − 0.78; all P < 0.05) were reported, as were improvements in ACR20 response rates (32.5–73.8% vs. 17.1–29.9%) [122, 123]. A second phase 2 study in 119 patients with RA reported greater improvements in all olokizumab treatment arms versus placebo for DAS28-CRP-defined improvements from baseline (all P < 0.0001) and ACR20 rates (all P < 0.05) at week 12 [123]. OLE studies of these phase 2 trials demonstrated that olokizumab was generally well tolerated and associated with sustained reductions from baseline in disease activity (DAS28-CRP) through 48 weeks (olokizumab: − 0.60 to − 0.68; placebo: − 1.70 to − 1.76) [124]. A pooled analysis of these phase 2 trials and their OLE studies indicated that both Western and Asian patients receiving olokizumab had greater improvements in patient-reported outcomes compared with placebo-treated patients at week 12; these improvements were sustained through 40 and 48 weeks during the OLE studies. For example, changes from baseline in HAQ-DI scores at weeks 12 and 48 were consistently greater with olokizumab than with placebo in 198 Western patients (− 0.32 and − 0.45 vs. − 0.07 and − 0.15) and in 105 Asian patients (− 0.41 and − 0.60 vs. 0 and − 0.28) patients [125].

Sirukumab

A phase 2 trial of sirukumab reported significant improvements in ACR50 response rates at week 24 for sirukumab 100 mg every 2 weeks (n = 17) versus placebo (n = 19) (26.7 vs. 3.3%; P < 0.05) and DAS28-CRP-defined improvements from baseline for all sirukumab dose groups versus placebo (2.0–2.2 vs. 1.0; all P < 0.001) in patients with RA and inadequate response to MTX [126].

The global, randomized, double-blind, phase 3 SIRROUND-H trial demonstrated significantly greater DAS28-ESR-defined improvements from baseline at week 24 with sirukumab 100 mg every 2 weeks (n = 187) and sirukumab 50 mg every 4 weeks (n = 186) versus adalimumab every 2 weeks (n = 186) (− 2.96 and − 2.58 vs. − 2.19; P < 0.001 and P = 0.013, respectively) in biologic-naive patients with RA who were intolerant of or inadequate responders to MTX. However, the second co-primary end point (ACR50 at week 24) was not met (35.3 and 26.9% vs. 31.7%; P = 0.464 and P = 0.306, respectively). Rates of SAEs were 2.7% for sirukumab 100 mg, 7.0% for sirukumab 50 mg, and 4.3% for adalimumab [127].

Although substantial evidence of efficacy is available for sirukumab in the RA setting, the U.S. FDA rejected its regulatory approval in September 2017 based on safety concerns over serious infections, malignancy, major adverse cardiac events, and abnormalities in laboratory tests, including a decreased neutrophil count. A trend of increased overall mortality for sirukumab over placebo was reported, which was mainly associated with major adverse cardiac events, infection, and malignancy [128].

Clazakizumab

Clazakizumab with or without MTX was evaluated in a phase 2b trial in 418 patients with RA and an inadequate response to MTX. Significant improvements in ACR20 response rates were observed for monotherapy with clazakizumab 100 and 200 mg and for combined clazakizumab 25, 100, and 200 mg + MTX therapy compared to MTX monotherapy (55.0, 61.0, 76.3, 73.3, and 60.0% vs. 39.3%; all P < 0.05) [129].

Vobarilizumab

The anti-IL-6R nanobody vobarilizumab (ALX-0061) is currently being evaluated as monotherapy (150 mg every 4 weeks, 150 mg every 2 weeks, or 225 mg every 2 weeks) in a randomized, head-to-head, phase 2b trial versus TCZ in patients with moderate to severe RA who were intolerant to MTX or for whom continued MTX treatment is inappropriate [130]. At week 12, ACR20 response rates were similar between the three vobarilizumab dose groups and TCZ (73–81 vs. 78%), although DAS28-ESR-defined remission rates appeared to be higher with the vobarilizumab 150 mg every 4 weeks and 225 mg every 2 weeks dosage groups versus TCZ (34 and 40% vs. 25%) [130].

In summary, two anti-IL-6R biologics have been approved for the treatment of RA, namely, TCZ and sarilumab, and multiple agents blocking the IL-6 signaling pathway are in development in this constantly changing field. Available data to date suggest that the newer agents may have similarities to TCZ; however, this inference is based mainly on data presented in abstract format, and it would therefore be premature and potentially misleading to compare efficacy and safety among these IL-6-targeted therapies. More data on the newer agents are eagerly awaited to inform physicians on the treatment of patients with RA and other diseases.

Conclusions

Tocilizumab is the first-in-class humanized anti-IL-6Rα monoclonal antibody to undergo global clinical development, resulting in its approval for the management of RA, Castleman’s disease, sJIA, pJIA, and GCA. In the RA setting, approval of TCZ was based on data from five pivotal phase 3 clinical trials that demonstrated its efficacy and safety in a range of patient populations, including inadequate responders to MTX and inadequate responders to TNF inhibitors. This review emphasizes recent developments with TCZ and other IL-6-targeted biologics; TCZ monotherapy has been evaluated, including in the early RA setting, and an SC formulation of TCZ was developed. Long-term safety studies have been encouraging, with no new toxicities identified and no difference in the frequencies of AEs and SAEs observed compared with those reported in pre-approval studies. Results reported to date suggest that TCZ has low immunogenicity.

TCZ has recently been approved for the treatment of GCA and is also being investigated for the treatment of SSc. However, TCZ was found not to be effective for the treatment of ankylosing spondylitis. Other off-label indications in which TCZ is being evaluated include RA-associated vasculitis, Takayasu arteritis, AOSD, PMR, Behçet’s disease, amyloidosis, FMF, Schnitzler’s syndrome, and polychondritis. However, limited data have been published for these diseases, and future prospective studies may determine whether there is a role for TCZ in the treatment of these diseases. Another IL-6 therapy, sarilumab, has been recently approved for the treatment of patients with RA who are inadequate responders to MTX/csDMARD, with comparable results to adalimumab. However, long-term data are still needed for this drug.

Novel IL-6 signaling-targeted biologics being developed have shown promise in the RA setting. However, the current lack of published data in the literature for these agents precludes accurate comparisons to data for TCZ. Well-designed clinical trials are needed to establish the efficacy and safety profiles of these newer agents; in particular, direct comparator studies to TCZ are needed.